Promoter Methylation Status of DAP-kinase and RUNX3 Genes in Neoplastic and Non-neoplastic Gastric Epithelia

Overview

Journal Cancer Sci

Specialty Oncology

Date 2003 Jun 26

PMID 12824905

Citations 38

Authors

Takayoshi Waki

Gen Tamura

Makoto Sato

Masanori Terashima

Satoshi Nishizuka

Teiichi Motoyama

Affiliations

Soon will be listed here.

Abstract

Silencing of tumor suppressor and tumor-related genes by hypermethylation at promoter CpG islands is frequently found in human tumors, including gastric cancer. Promoter methylation is not restricted to cancer cells, and is also present in non-neoplastic cells as an age-related tissue-specific phenomenon. To clarify the physiological consequence of DAP-kinase and RUNX3 age-related methylation in gastric epithelia, we investigated the promoter methylation status of these genes in both neoplastic and non-neoplastic gastric epithelia obtained at autopsy and surgery, as well as in 10 gastric cancer cell lines. Methylation of DAP-kinase and RUNX3 was detected in 10% (1/10) and 70% (7/10) of the cell lines, respectively, and was almost concordant with their expression status. Among autopsy samples, methylation of these genes was not seen in non-neoplastic gastric epithelia from persons who were aged 22 years and below (0%; 0/4). DAP-kinase was methylated in 87% (13/15) of non-neoplastic gastric epithelia of persons who were aged 45 years or older, while RUNX3 methylation in non-neoplastic gastric epithelia was restricted to individuals who were aged 77 years or older. Among samples obtained from patients with stomach cancer, methylation was observed in both the neoplastic and the corresponding non-neoplastic gastric epithelia; 43% (40/93) and 73% (68/93) for DAP-kinase, and 45% (42/93) and 8% (7/93) for RUNX3, respectively. Frequencies of DAP-kinase and RUNX3 methylation differed significantly in non-neoplastic gastric epithelia (P < 0.01), although those in gastric cancers were almost the same. RUNX3 methylation is mostly cancer-specific, except for very old individuals, and therefore may be a possible molecular diagnostic marker and malignancy predictor.

Citing Articles

Aberrant hydroxymethylation in promoter CpG regions of genes related to the cell cycle and apoptosis characterizes advanced chronic myeloid leukemia disease, poor imatinib respondents and poor survival.

Guru S, Sumi M, Mir R, Ali Beg M, Koner B, Saxena A BMC Cancer. 2022; 22(1):405.

PMID: 35421941 PMC: 9008925. DOI: 10.1186/s12885-022-09481-9.

Lina M, Changan W, Qing Z Open Life Sci. 2021; 13:64-70.

PMID: 33817069 PMC: 7874703. DOI: 10.1515/biol-2018-0009.

Downregulation of () follows the stepwise progression to gastric adenocarcinoma.

Del Portillo A, Komissarova E, Bokhari A, Hills C, Koehne de Gonzalez A, Kongkarnka S Oncotarget. 2019; 10(39):3852-3864.

PMID: 31231464 PMC: 6570468. DOI: 10.18632/oncotarget.26974.

levels in human hematopoietic progenitors are regulated by aging and dictate erythroid-myeloid balance.

Balogh P, Adelman E, Pluvinage J, Capaldo B, Freeman K, Singh S Haematologica. 2019; 105(4):905-913.

PMID: 31171641 PMC: 7109730. DOI: 10.3324/haematol.2018.208918.

RUNX3 enhances TRAIL-induced apoptosis by upregulating DR5 in colorectal cancer.

Kim B, Park S, Jeong Y, Na Y, Kim J, Jo M Oncogene. 2019; 38(20):3903-3918.

PMID: 30692634 DOI: 10.1038/s41388-019-0693-x.

References

Honda T, Tamura G, Waki T, Jin Z, Sato K, Motoyama T . Hypermethylation of the TSLC1 gene promoter in primary gastric cancers and gastric cancer cell lines. Jpn J Cancer Res. 2003; 93(8):857-60. PMC: 5927103. DOI: 10.1111/j.1349-7006.2002.tb01329.x. View

Toyota M, Ahuja N, Suzuki H, Itoh F, Imai K, Baylin S . Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res. 1999; 59(21):5438-42. View

Issa J, Ottaviano Y, Celano P, Hamilton S, Davidson N, Baylin S . Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet. 1994; 7(4):536-40. DOI: 10.1038/ng0894-536. View

Tang X, Khuri F, Lee J, Kemp B, Liu D, Hong W . Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst. 2000; 92(18):1511-6. DOI: 10.1093/jnci/92.18.1511. View

Suzuki H, Itoh F, Toyota M, Kikuchi T, Kakiuchi H, Hinoda Y . Distinct methylation pattern and microsatellite instability in sporadic gastric cancer. Int J Cancer. 1999; 83(3):309-13. DOI: 10.1002/(sici)1097-0215(19991029)83:3<309::aid-ijc4>3.0.co;2-z. View

Cohen O, Kimchi A . DAP-kinase: from functional gene cloning to establishment of its role in apoptosis and cancer. Cell Death Differ. 2001; 8(1):6-15. DOI: 10.1038/sj.cdd.4400794. View

Issa J, Vertino P, Boehm C, Newsham I, Baylin S . Switch from monoallelic to biallelic human IGF2 promoter methylation during aging and carcinogenesis. Proc Natl Acad Sci U S A. 1996; 93(21):11757-62. PMC: 38131. DOI: 10.1073/pnas.93.21.11757. View

Satoh A, Toyota M, Itoh F, Kikuchi T, Obata T, Sasaki Y . DNA methylation and histone deacetylation associated with silencing DAP kinase gene expression in colorectal and gastric cancers. Br J Cancer. 2002; 86(11):1817-23. PMC: 2375414. DOI: 10.1038/sj.bjc.6600319. View

Cohen Jr M . RUNX genes, neoplasia, and cleidocranial dysplasia. Am J Med Genet. 2001; 104(3):185-8. View

10.

Schneider B, Gulley M, Eagan P, Bravo J, Mera R, Geradts J . Loss of p16/CDKN2A tumor suppressor protein in gastric adenocarcinoma is associated with Epstein-Barr virus and anatomic location in the body of the stomach. Hum Pathol. 2000; 31(1):45-50. DOI: 10.1016/s0046-8177(00)80197-5. View

11.

Tamura G, Yin J, Wang S, Fleisher A, Zou T, Abraham J . E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst. 2000; 92(7):569-73. DOI: 10.1093/jnci/92.7.569. View

12.

Razin A, Cedar H . DNA methylation and gene expression. Microbiol Rev. 1991; 55(3):451-8. PMC: 372829. DOI: 10.1128/mr.55.3.451-458.1991. View

13.

Esteller M, Corn P, Baylin S, Herman J . A gene hypermethylation profile of human cancer. Cancer Res. 2001; 61(8):3225-9. View

14.

Ahuja N, Li Q, Mohan A, Baylin S, Issa J . Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res. 1998; 58(23):5489-94. View

15.

Kang G, Shim Y, Jung H, Kim W, Ro J, Rhyu M . CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res. 2001; 61(7):2847-51. View

16.

Fleisher A, Esteller M, Wang S, Tamura G, Suzuki H, Yin J . Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res. 1999; 59(5):1090-5. View

17.

Li Q, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi X . Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell. 2002; 109(1):113-24. DOI: 10.1016/s0092-8674(02)00690-6. View

18.

Toyota M, Ahuja N, Herman J, Baylin S, Issa J . CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999; 96(15):8681-6. PMC: 17576. DOI: 10.1073/pnas.96.15.8681. View

19.

Jones P, Laird P . Cancer epigenetics comes of age. Nat Genet. 1999; 21(2):163-7. DOI: 10.1038/5947. View

20.

Nakagawa H, Nuovo G, Zervos E, Martin Jr E, Salovaara R, Aaltonen L . Age-related hypermethylation of the 5' region of MLH1 in normal colonic mucosa is associated with microsatellite-unstable colorectal cancer development. Cancer Res. 2001; 61(19):6991-5. View